

## Apotex – Recall of brimonidine tartrate ophthalmic solution

- On March 1, 2023, <u>Apotex Corp. announced</u> a consumer-level recall of six lots of <u>brimonidine</u> <u>tartrate</u> ophthalmic solution 0.15% due to cracks that have developed in some of the units caps of bottles that may impact sterility and if so, the possibility of adverse events.
  - Other brimonidine tartrate ophthalmic solution products made by other manufacturers that are not being recalled are available for use.
- These lots were distributed nationwide between April 05, 2022 to February 22, 2023.

Product Description	NDC#	Lot# (Expiration Date)
Brimonidine tartrate ophthalmic solution 0.15%, 5 mL	60505-0564-1	TJ9848 (2/2024) TJ9849 (2/2024) TK0258 (4/2024) TK5341 (4/2024)
Brimonidine tartrate ophthalmic solution 0.15%, 10 mL	60505-0564-2	TK0261 (4/2024)
Brimonidine tartrate ophthalmic solution 0.15%, 15 mL	60505-0564-3	TK0262 (4/2024)

- Brimonidine tartrate ophthalmic solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Patients who are currently using the recalled brimonidine tartrate ophthalmic solution should stop
  use and contact their pharmacy for a replacement. Patients should contact their physician or
  healthcare provider if they have experienced any problems that may be related to using the
  recalled product.
- Anyone with an existing inventory of the recalled product should stop use, distribution, and quarantine the product immediately and arrange for return.
- Contact Apotex Corp. by phone at 1-800-706-5575 or by e-mail at <u>UScustomerservice@Apotex.com</u> for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.